Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
J Intern Med. 2011 Mar;269(3):340-8. doi: 10.1111/j.1365-2796.2010.02308.x. Epub 2010 Nov 16.
The scavenger receptor A-I/II (SRA-I/II) on alveolar macrophages is involved in recognition and clearance of modified lipids and inhaled particulates. A rare variant of the SRA-I/II gene, Arg293X, truncates the distal collagen-like domain, which is essential for ligand recognition. We tested whether the Arg293X variant is associated with reduced lung function and risk of chronic obstructive pulmonary disease (COPD) in the general population.
We genotyped 48,741 individuals from the adult Danish general population for Arg293X, and recorded lung function and spirometry-defined COPD.
Arg293X homozygotes (n = 5) and heterozygotes (n = 587), compared with noncarriers (n = 48,149), had a 6% and 1% reduction in predicted percentage of forced vital capacity (FVC % predicted) (P = 0.05) and a nonsignificant 7% and 1% reduction in predicted percentage of forced expiratory volume in one second (FEV(1) % predicted) (P = 0.06), respectively. The Arg293X genotype interacted with gender (P = 0.004) and α(1) -antitrypsin MZ heterozygosity (P = 0.049), but not with superoxide dismutase-3 E1I1 heterozygosity (P = 0.11) in determining FEV(1) % predicted. Amongst men, FEV(1) % predicted and FVC % predicted were both reduced by 4% (P = 0.0004 and P = 0.0003, respectively) in Arg293X heterozygotes compared with noncarriers. Corresponding values were 14% (P = 0.03) and 11% (P = 0.04) amongst MZ heterozygotes, and 9% (P = 0.03) and 8% (P = 0.04) amongst E1I1 heterozygotes, compared with noncarriers. Lung function did not differ between Arg293X heterozygotes and noncarriers amongst females or individuals without MZ and E1I1. Arg293X heterozygosity was associated with spirometry-defined COPD amongst men [odds ratio (95% confidence interval): 1.7 (1.1-2.4)], but not with COPD in the whole cohort or in any other subgroup.
SRAI/II Arg293X heterozygotes have reduced lung function and increased COPD risk amongst men. They also have reduced lung function amongst individuals heterozygous for the α(1)-antitrypsin MZ and superoxide dismutase-3 E1I1 genotypes.
肺泡巨噬细胞上的清道夫受体 A-I/II(SRA-I/II)参与识别和清除修饰后的脂质和吸入的颗粒物。SRA-I/II 基因的一个罕见变体 Arg293X 截断了远端胶原样结构域,该结构域对配体识别至关重要。我们检测了 Arg293X 变体是否与一般人群中的肺功能降低和慢性阻塞性肺疾病(COPD)风险相关。
我们对丹麦成年人群中的 48741 人进行了 Arg293X 的基因分型,并记录了肺功能和肺活量计定义的 COPD。
与非携带者(n=48149)相比,Arg293X 纯合子(n=5)和杂合子(n=587)的预计用力肺活量百分比(FVC%预测值)分别降低了 6%和 1%(P=0.05),预计 1 秒用力呼气量百分比(FEV1%预测值)分别降低了 7%和 1%(P=0.06)。Arg293X 基因型与性别(P=0.004)和α1-抗胰蛋白酶 MZ 杂合性(P=0.049)相互作用,但与超氧化物歧化酶-3 E1I1 杂合性(P=0.11)无关,从而决定了 FEV1%预测值。在男性中,与非携带者相比,Arg293X 杂合子的 FEV1%预测值和 FVC%预测值均降低了 4%(P=0.0004 和 P=0.0003)。在 MZ 杂合子中,相应值分别为 14%(P=0.03)和 11%(P=0.04),在 E1I1 杂合子中,相应值分别为 9%(P=0.03)和 8%(P=0.04),而非携带者。在女性或没有 MZ 和 E1I1 的个体中,Arg293X 杂合子与非携带者之间的肺功能无差异。Arg293X 杂合性与男性的肺活量计定义的 COPD 相关(比值比(95%置信区间):1.7(1.1-2.4)),但与整个队列或任何其他亚组的 COPD 无关。
SRAI/II Arg293X 杂合子的男性肺功能降低,COPD 风险增加。在携带α1-抗胰蛋白酶 MZ 和超氧化物歧化酶-3 E1I1 基因型的杂合子中,他们的肺功能也降低。